Omichi Kiyohiko, Cloyd Jordan M, Yamashita Suguru, Tzeng Ching-Wei D, Conrad Claudius, Chun Yun Shin, Aloia Thomas A, Vauthey Jean-Nicolas
Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX.
Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX.
Surgery. 2017 Oct;162(4):752-765. doi: 10.1016/j.surg.2017.05.015. Epub 2017 Jul 5.
Previous studies have demonstrated a strong association between the preoperative neutrophil-to-lymphocyte ratio and the outcomes of patients with resected hepatocellular carcinoma and colorectal liver metastases. However, the predictive ability of neutrophil-to-lymphocyte ratio in patients with intrahepatic cholangiocarcinoma, especially those treated with preoperative chemotherapy, has been less well described.
The clinicopathological characteristics, overall survival, and recurrence free survival of all patients with intrahepatic cholangiocarcinoma resected between 2000-2015, were compared between those with elevated (≥3.0) and normal (<3.0) neutrophil-to-lymphocyte ratio.
Among 119 patients who met the inclusion criteria, 64 (53.8%) had neutrophil-to-lymphocyte ratio <3.0 and 55 (46.2%) had neutrophil-to-lymphocyte ratio ≥3.0. Patients with neutrophil-to-lymphocyte ratio ≥3.0 were more likely to be female and have lymph node metastasis (P < .05). Cumulative 5-year overall survival and recurrence free survival rates were 87% and 60%, respectively in patients with neutrophil-to-lymphocyte ratio <3.0, compared with 64% and 39%, respectively in patients with neutrophil-to-lymphocyte ratio ≥3.0 (P = .049 and .038). Among 43 patients treated with preoperative chemotherapy and resection, 21 (48.8%) had neutrophil-to-lymphocyte ratio <3.0 and 22 (51.2%) had neutrophil-to-lymphocyte ratio ≥3.0. In this subgroup, cumulative 5-year overall survival and recurrence free survival rates were 95% and 70%, respectively in the patients with neutrophil-to-lymphocyte ratio <3.0 compared with 50% and 26%, respectively in the patients with neutrophil-to-lymphocyte ratio ≥3.0 (P = .002 and P = .004). On multivariate analysis, a neutrophil-to-lymphocyte ratio ≥3.0 was associated significantly with worse overall survival among all patients as well as overall survival and recurrence free survival among the subgroup who received preoperative chemotherapy.
Neutrophil-to-lymphocyte ratio is associated independently with worse survival in patients with intrahepatic cholangiocarcinoma undergoing resection or neoadjuvant chemotherapy prior to resection.
既往研究表明,术前中性粒细胞与淋巴细胞比值与肝细胞癌切除患者及结直肠癌肝转移患者的预后密切相关。然而,中性粒细胞与淋巴细胞比值在肝内胆管癌患者中的预测能力,尤其是在接受术前化疗的患者中,尚未得到充分描述。
比较2000年至2015年间接受肝内胆管癌切除术的所有患者中,中性粒细胞与淋巴细胞比值升高(≥3.0)和正常(<3.0)患者的临床病理特征、总生存期和无复发生存期。
在119例符合纳入标准的患者中,64例(53.8%)中性粒细胞与淋巴细胞比值<3.0,55例(46.2%)中性粒细胞与淋巴细胞比值≥3.0。中性粒细胞与淋巴细胞比值≥3.0的患者更可能为女性且有淋巴结转移(P<0.05)。中性粒细胞与淋巴细胞比值<3.0的患者5年累积总生存率和无复发生存率分别为87%和60%,而中性粒细胞与淋巴细胞比值≥3.0的患者分别为64%和39%(P=0.049和0.038)。在43例接受术前化疗和切除术的患者中,21例(48.8%)中性粒细胞与淋巴细胞比值<3.0,22例(51.2%)中性粒细胞与淋巴细胞比值≥3.0。在该亚组中,中性粒细胞与淋巴细胞比值<3.0的患者5年累积总生存率和无复发生存率分别为95%和70%,而中性粒细胞与淋巴细胞比值≥3.0的患者分别为50%和26%(P=0.002和P=0.004)。多因素分析显示,中性粒细胞与淋巴细胞比值≥3.0与所有患者的总生存期较差以及接受术前化疗亚组的总生存期和无复发生存期较差显著相关。
中性粒细胞与淋巴细胞比值与接受切除术或术前新辅助化疗的肝内胆管癌患者的较差生存独立相关。